Men Haitao, Liang Chunshui, Yu Min
Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
J Cancer Res Ther. 2015 Jan-Mar;11(1):67-72. doi: 10.4103/0973-1482.150345.
The aim of this study was to analyze the prognostic implications of perioperative thrombocytosis in patients with renal cell carcinoma (RCC).
We conducted search on two medical databases, PubMed and EMBASE, to identify all studies. A meta-analysis was performed to clarify the prognostic role of thrombocytosis.
Twelve studies (N = 8735) were included which evaluated the relation of thrombocytosis and 5-year overall survival (OS) or cancer-specific survival (CSS). One thousand and fifty-nine (12.1%) of the 8735 patients exhibited thrombocytosis, and for OS, their estimated risk of death in 5 years was 1.61-fold higher compared with the normal platelet count group [(RR = 1.61, 95% CI = (1.31-1.98), P < 0.001)]. While for CSS, the mortality was 2.56-fold higher [(RR = 2.56, 95% CI = (1.73-3.80), P < 0.00001). According to subgroup analyses, significant positive influence of thrombocytosis on 5-year OS and CSS was displayed only in patients with localized RCC and was also found in patients originated from different areas, such as Asian, Europe or North American.
Thrombocytosis indicates worse OS and CSS for patients with RCC, and it showed stronger specificity or sensitivity for CSS. Thrombocytosis is more frequently in patients with metastatic RCC but only showed significant influence on survival of localized RCC patients.
本研究旨在分析肾细胞癌(RCC)患者围手术期血小板增多症的预后意义。
我们在两个医学数据库PubMed和EMBASE上进行检索,以确定所有研究。进行荟萃分析以阐明血小板增多症的预后作用。
纳入了12项研究(N = 8735),这些研究评估了血小板增多症与5年总生存期(OS)或癌症特异性生存期(CSS)的关系。8735例患者中有1059例(12.1%)出现血小板增多症,对于OS,他们5年内的估计死亡风险比正常血小板计数组高1.61倍[(RR = 1.61,95%CI =(1.31 - 1.98),P < 0.001)]。而对于CSS,死亡率高2.56倍[(RR = 2.56,95%CI =(1.73 - 3.80),P < 0.00001)]。根据亚组分析,血小板增多症仅在局限性RCC患者中对5年OS和CSS显示出显著的正向影响,并且在来自不同地区(如亚洲、欧洲或北美)的患者中也发现了这种影响。
血小板增多症表明RCC患者的OS和CSS较差,并且它对CSS显示出更强的特异性或敏感性。血小板增多症在转移性RCC患者中更常见,但仅对局限性RCC患者的生存有显著影响。